Vir CEO Sees Chance for More Deals After $1.9B Gilead Pact for Dual-Masked T-Cell Engagers

Vir Biotechnology and Gilead partner on dual-masked T-cell engagers for solid tumors in a deal worth up to $1.9B, as Vir’s CEO sees more partnership opportunities.